Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.

Journal of clinical pharmacy and therapeutics - 1 Feb 2018

Millar B C, McCaughan J, Rendall J C, Downey D G, Moore J E

Abstract excerpt

WHAT IS KNOWN AND OBJECTIVE: The CFTR potentiator, ivacaftor (IVA), has been widely used in the treatment of cystic fibrosis (CF) patients with the G551D mutation. To date, there has been limited information on the microbiological status of patients on this therapy and no data on the effect (if any) on the in vivo antibiotic susceptibility of Pseudomonas aeruginosa isolated from patients on therapy. Although IVA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Anti-Bacterial Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Microbial Sensitivity Tests

Share to Pseudomonas aeruginosa

Share to Pseudomonas Infections

Share to Quinolones

Source

Identifiers

PMID: 29293275
DOI: 10.1111/jcpt.12616

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.PMID 29293275Read ↗

Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With IvacaftorSemantic proximity Read ↗

Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.Semantic proximity Read ↗

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.Semantic proximity Read ↗

[Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].Semantic proximity Read ↗

Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.Semantic proximity Read ↗

Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease.Semantic proximity Read ↗

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.Semantic proximity Read ↗

Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal InflammationSemantic proximity Read ↗

Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N MutationSemantic proximity Read ↗

Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.Semantic proximity Read ↗

Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis.Semantic proximity Read ↗

Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.